

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of Sinopharm Tech Holdings Limited.



SINOPHARM TECH HOLDINGS LIMITED

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

DELAY IN DESPATCH OF CIRCULAR

References are made to the announcements of Sinopharm Tech Holdings Limited (the “**Company**”) dated 18 February 2021 (the “**Announcement**”) and 17 March 2021, respectively, in relation to (i) the discloseable and connected transaction in relation to the acquisition of 25% equity interest in Rich General Limited involving the issue of Consideration Shares under specific mandate; and (ii) the continuing connected transaction of the Company. Terms used herein shall have the same meanings as those defined in the Announcement, unless otherwise specified.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among others, (i) further details of the Sale and Purchase Agreement and the transactions contemplated thereunder; (ii) further details of the Licensing and Master Service Agreement and the transactions contemplated thereunder; and (iii) a notice convening the EGM will be despatched to the Shareholders on or before 31 March 2021.

As additional time is required for the Company to prepare and finalise certain information to be included in the Circular, it is expected that the despatch date of the Circular will be delayed to a date falling on or before 14 May 2021.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 31 March 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting as executive Director; Madam CHEUNG Kwai Lan, Mr. CHAN Tung Mei and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as the independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.